Remarkably, an antibody cocktail-based immunotherapy that combines checkpoint blockade with dual-targeting of IL-6 and CD40 resulted in the extension of animal survival in two syngeneic GBM mice models [152]. The gene discussed is IL6; the disease is glioblastoma.